TSX:ONC Archives - Spark Newswire

1 minute read

June 20, 7:28 AM

SAN DIEGO, and CALGARY, AB, June 20, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), a leading clinical-stage company specializing in immunotherapeutics for oncology,

ONCY

4 minute read

The Pancreatic Cancer Action Network Selects Oncolytics Biotech Inc. To Receive $5M Therapeutic Accelerator Award To Develop Leading-Edge Treatments

By Benzinga Newsdesk

September 26, 8:01 AM

Innovative Multimillion-Dollar Grant Was Created in 2022 to Drive Biopharma Industry to Speed Development of Pancreatic Cancer TherapiesBOSTON and SAN DIEGO and CALGARY, AB, Sept. 26, 2023 /PRNewswire/ -- In an effort to

ONCY

1 minute read

Oncolytics Biotech Announces Upcoming Oral Presentation On Randomized BRACELET-1 Trial In HR+/HER2- Metastatic Breast Cancer At The ASCO Annual Meeting

By Happy Mohamed

April 26, 10:45 AM

Oral presentation on BRACELET-1 to take place on June 3, 2023

ONCY

1 minute read

Cantor Fitzgerald Initiates Coverage On Oncolytics Biotech with Overweight Rating, Announces Price Target of C$9

By Benzinga Newsdesk

March 6, 7:21 AM

Cantor Fitzgerald analyst Louise Chen initiates coverage on Oncolytics Biotech (TSX:ONC) with a Overweight rating and announces Price Target of C$9.

TSX:ONC

3 minute read

Oncolytics Biotech’s Chinese Development Partner Adlai Nortye Presents Interim Clinical Data Further Demonstrating The Anti-Cancer Activity Of Pelareorep-Paclitaxel Combination Therapy In HR+/HER2- Metastatic Breast Cancer At SABCS

By Benzinga Newsdesk

December 8, 9:58 AM

Thirteen of fourteen (93%) evaluable patients achieved disease control, with twelve (86%) showing tumor shrinkage SAN DIEGO and CALGARY, AB, Dec. 8, 2022 /CNW/ -- Oncolytics

ONCY

2 minute read

Oncolytics Biotech Receives FDA Fast Track Designation For The Treatment Of Advanced/Metastatic Pancreatic Cancer

By Benzinga Newsdesk

December 1, 8:40 AM

Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to pelareorep in combination with Roche's anti-PD-L1

ONCY

Feed Symbols: TSX:ONC

Oncolytics Biotech Begins New Study for Advanced Pancreatic Cancer Treatment

The Pancreatic Cancer Action Network Selects Oncolytics Biotech Inc. To Receive $5M Therapeutic Accelerator Award To Develop Leading-Edge Treatments

Oncolytics Biotech Announces Upcoming Oral Presentation On Randomized BRACELET-1 Trial In HR+/HER2- Metastatic Breast Cancer At The ASCO Annual Meeting

Cantor Fitzgerald Initiates Coverage On Oncolytics Biotech with Overweight Rating, Announces Price Target of C$9

Oncolytics Biotech’s Chinese Development Partner Adlai Nortye Presents Interim Clinical Data Further Demonstrating The Anti-Cancer Activity Of Pelareorep-Paclitaxel Combination Therapy In HR+/HER2- Metastatic Breast Cancer At SABCS

Oncolytics Biotech Receives FDA Fast Track Designation For The Treatment Of Advanced/Metastatic Pancreatic Cancer